Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Urologic Neoplasms × Afatinib × Genitourinary × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 3 Urologic Neoplasms 1 Urinary Bladder Neoplasms 1 Urethral Neoplasms 1 Ureteral Neoplasms 1 Thrombocytosis 1 Primary Myelofibrosis 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Pancreatic Neoplasms 1 Neoplasms 1 Neoplasm Metastasis 1 NSCLC Harboring NRG1 Fusion 1 Myeloproliferative Disorders 1 Myelodysplastic-Myeloproliferative Diseases 1 Myelodysplastic Syndromes 1 Multiple Myeloma 1 Lymphoma, Non-Hodgkin 1 Leukemia, Myelomonocytic, Chronic 1 Leukemia, Myeloid, Chronic-Phase 1 Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1 Leukemia, Myeloid, Acute 1 Leukemia, Myeloid, Accelerated Phase 1 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Hodgkin Disease 1 Hematologic Neoplasms 1 Carcinoma, Transitional Cell 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1 Blast Crisis 1

Interventions

Gemcitabine 7 pembrolizumab 4 atezolizumab 3 Trastuzumab 3 Sunitinib 3 Carboplatin 3 enfortumab vedotin 2 dodecyl maltoside 2 cabozantinib 2 Water 2 Standard of Care 2 Pemetrexed 2 Paclitaxel 2 Cisplatin 2 Cetuximab 2 Bevacizumab 2 vinflunine 1 valrubicin 1 tislelizumab 1 testosterone 17 beta-cypionate 1 temsirolimus 1 poly ICLC 1 niraparib 1 montanide ISA 51 1 lenvatinib 1 flt3 ligand protein 1 delta 24-sterol reductase 1 daratumumab 1 avelumab 1 abemaciclib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02780687 2020-11-18

LUX-Bladder 1

Boehringer Ingelheim

Phase 2 Completed

42 enrolled 16 charts

Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡